BeOne Medicines AG (ONC) fair value analysis
Nasdaq · Updated 2026-10-19
ONC price how computed
Valuation status
Awaiting full valuationONC does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards.
We require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $369.06
- Sector
- Healthcare
- 12-month range
- $260.27–$377.47
- Market cap
- $38.7B
- From 52-week high
- -2.2%
- Shares outstanding
- 105M
- Rank in Healthcare by quality score
- #6 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
BeOne Medicines AG is a biopharmaceutical company that focuses on the development of therapies for oncology and other serious diseases. The company is headquartered in Switzerland and operates as a publicly traded entity on the Nasdaq stock exchange.
ONC currently ranks #6 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $38.7B
- P/E (trailing)
- 65x
- Revenue (TTM)
- $6.13B
- Net margin
- 10.7%
- EPS (TTM)
- $5.68
- Gross margin
- 89.8%
- Debt / equity
- 0.22
- Revenue growth (3-yr avg)
- 39.4%
- Shares outstanding
- 105M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 60 · neutral
- 50-day average
- $360.22
- 200-day average
- $322.54
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+46.4%)
2026-03 ▲ beat (+142.0%)
2025-12 ▼ miss (-63.7%)
2025-09 ▲ beat (+26.7%)
2025-06 ▲ beat (+223.1%)
2025-03 ▲ beat (+101.4%)
2024-12 ▼ miss (-41.6%)
2024-09 ▼ miss (-3.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 27 buy · 1 hold · 0 sell (28 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $436
- Target vs last price
- +18.1%
What our data shows for ONC
- Our model validated 2 trailing price-to-earnings windows for ONC, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $260.27–$377.47.
- The 14-day relative strength index sits at a neutral 60.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ONC's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the ONC conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — ONC's 50/200-day trend state shifted from mixed to uptrend this week, reflecting improved short-term momentum relative to longer-term price direction. The Healthcare sector company remains under a valuation verdict of awaiting full valuation, indicating that comprehensive valuation assessment is pending based on TickrTrends' derived indicators.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — ONC's 50/200-day trend state shifted from an uptrend to a mixed trend this week, indicating a change in momentum according to TickrTrends' derived indicators. This transition suggests the stock's shorter-term price movement has diverged from its longer-term trajectory. The valuation assessment for ONC remains pending full evaluation.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ONC stock undervalued?
ONC does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is ONC's TickrTrends verdict?
ONC is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does ONC compare to other Healthcare stocks?
ONC ranks #6 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ONC overbought or oversold?
ONC's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ONC report earnings next?
ONC's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does ONC usually beat earnings estimates?
Over its last 8 reported quarters ONC beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ONC?
Of 28 analysts covering ONC, 27 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $436 (+18.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.